Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Observational × empagliflozin × Clear all

Status

Sponsor Class

Study Type

Interventional 8 Observational 1

Sponsor

Conditions

Diabetes Mellitus, Type 2 1

Interventions

Surveys and Questionnaires 540 Blood Specimen Collection 443 Surgical Procedures, Operative 160 Observation 144 Drug Therapy 140 Radiotherapy 139 Interviews as Topic 138 Gene Expression Profiling 129 Biopsy 116 Magnetic Resonance Spectroscopy 115 Immunohistochemistry 110 Data Collection 94 Polymerase Chain Reaction 87 Amplified Fragment Length Polymorphism Analysis 81 Specimen Handling 80 Bevacizumab 78 Microarray Analysis 76 Flow Cytometry 68 Neoadjuvant Therapy 66 Magnetic Resonance Imaging 66 Watchful Waiting 65 Nivolumab 60 Immune Checkpoint Inhibitors 60 Immunotherapy 56 Therapeutics 54 Reverse Transcriptase Polymerase Chain Reaction 52 pembrolizumab 50 Ultrasonography 47 Positron Emission Tomography Computed Tomography 47 Hematologic Tests 46

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03464045 2025-04-20

Empa PASS on Urinary Tract Malignancies

Boehringer Ingelheim

344,995 enrolled 12 charts

Diabetes Mellitus, Type 2

Data powered by HemOnc (CC BY 4.0) Colophon ⚡